5 Key Takeaways
-
1
Photobiomodulation (PBM) is a novel treatment for early- to intermediate-stage dry age-related macular degeneration (AMD) with positive clinical trial results.
-
2
LumiThera’s Valeda Light Delivery System received FDA authorization in November 2024 for treating dry AMD and geographic atrophy.
-
3
PBM improves vision without requiring anesthesia, allowing the procedure to be performed in medical clinics rather than surgical centers.
-
4
The new Category III CPT code 0936T for PBM will be effective from January 1, 2025, reporting a single session treatment for reimbursement.
-
5
An eye exam with dilation is required before PBM to establish medical necessity, and patients must be informed about potential financial responsibility.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.